Indications -- Cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (24)	5/12/2001 5:05:15 PM
From: Miljenko Zuanic	Read Replies (3) of 1840

<<Though you earlier said no more talk on c225, I take Message #23 as a small opening.>> Just short note on today news: biz.yahoo.com <<In an oral presentation, Leonard Saltz, M.D., Associate Attending Physician, Memorial Sloan-Kettering Cancer Center, and Principal Investigator of the study, presented findings from the study that treated 120 patients with the combination of IMC-C225 and irinotecan. All of the patients had failed irinotecan therapy prior to joining the study. The findings demonstrated that 27 patients (22.5 percent) achieved a partial response, and an additional 9 patients (7.5 percent) achieved a stabilization of disease. The median duration of response is 186 days. >> Does failed means progresive or broad non-responded? Seams to me that data are bit short from expectation. Very small percentage of the stable disease and not very long median response duration (no idea what was median survival, but results indicate that they are bit short as well) may swing several of the border +50% reduction (clasified as partial responded) into stable disease category (by FDA)??? This are not a clear NDA results, so far, and IMO. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next